US
Updated
Reviewed by Chandani Patel
US Celiac Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Approach, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $411.7 Mn.
Canada at 9.2% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$364.5 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $383.7 Mn | — | — |
| 2025 (base) | $411.7 Mn | +$28.0 Mn | — |
| 2026 (forecast) | $441.8 Mn | +$30.1 Mn | +7.3% |
| 2027 (forecast) | $474.0 Mn | +$32.2 Mn | +15.1% |
| 2028 (forecast) | $508.6 Mn | +$34.6 Mn | +23.5% |
| 2029 (forecast) | $545.8 Mn | +$37.1 Mn | +32.6% |
| 2030 (forecast) | $585.6 Mn | +$39.8 Mn | +42.2% |
| 2031 (forecast) | $628.3 Mn | +$42.7 Mn | +52.6% |
| 2032 (forecast) | $674.2 Mn | +$45.9 Mn | +63.8% |
| 2033 (forecast) | $723.4 Mn | +$49.2 Mn | +75.7% |
| 2034 (forecast) | $776.2 Mn | +$52.8 Mn | +88.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$411.7 Mn
China
$88.3 Mn
Canada
$86.0 Mn
Japan
$68.0 Mn
Germany
$35.7 Mn
Brazil
$27.3 Mn
France
$25.1 Mn
Italy
$23.9 Mn
UK
$21.1 Mn
India
$19.5 Mn
Spain
$17.7 Mn
Ecuador
$17.8 Mn
Saudi Arabia
$16.1 Mn
Mexico
$13.5 Mn
Australia
$11.7 Mn
Russia
$9.0 Mn
New Zealand
$8.7 Mn
South Africa
$6.8 Mn
UAE
$4.1 Mn
Egypt
$2.6 Mn
Philippines
$2.3 Mn
Hong Kong
$1.5 Mn
Malaysia
$1.4 Mn
Singapore
$1.2 Mn
Thailand
$1.1 Mn
Kenya
$0.6 Mn
| Market size, 2025 | $411.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $776.2 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 7.3% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Approach, age and end user (see all) |
| Key players | Takeda Pharmaceutical Company Ltd, Anokion, Teva Pharmaceutical, ImmunogenX, Dr. Schar (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Active clinical trials | 18 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Celiac disease treatment today is a gluten-free diet, with new medicines in development to protect the gut from gluten.
Key segments of the celiac Disease Treatment market include approach (Gluten-Free Diet Products, Enzyme Therapies and Tolerance Therapies) and age (Children and Adults).
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the celiac Disease Treatment market. Biosimilars are widening access.
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the celiac Disease Treatment market room to grow.
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the celiac Disease Treatment market.
The celiac Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2] ClinicalTrials.gov lists 18 studies on Celiac Disease Treatment that are recruiting, active or about to start in the US.[3]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for celiac Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Celiac Disease Treatment right now, from free public sources.
18 active trials in the US
Recruiting, about to start, or running now.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
US · 2 shared keywords
OTC & Nutraceuticals · US
Medical Devices · US
OTC & Nutraceuticals · US
OTC & Nutraceuticals · US
Medical Devices · US
OTC & Nutraceuticals · US
Amneal Pharmaceuticals, Inc
Dr Reddy’s Laboratories